Special Issue "Vaccines and Therapeutics against Coronaviruses"
Deadline for manuscript submissions: 30 June 2021.
Interests: viral gene therapy; viral vaccines; gene expression using viral vectors; structural biology; epigenetics; nutrigenomics
Special Issues and Collections in MDPI journals
Special Issue in Diseases: Gene Therapy
Special Issue in Biomedicines: Gene Therapy Coming of Age
Special Issue in Viruses: RNA Interference (RNAi) for Antiviral Therapy
The current COVID-19 pandemic has caused unprecedented devastation to health and the economy around the world, and is expected to continue for an unforeseen time into the future due to the lack of existing antiviral drugs and vaccines. In a unique cooperation between academic institutions, pharmaceutical and biotech enterprises, and governmental organizations, the research and development of vaccines and therapeutics against COVID-19 is occurring at a level never seen before. This research has generated plenty of new information on COVID-19 as well as SARS-CoV-2, responsible for the pandemic, as illustrated by the 74,417 publications found in PubMed when using the search term “COVID-19”. Today, some drugs have demonstrated specific efficacy in the treatment of seriously ill COVID-19 patients, and two vaccine candidates have shown promising primary results in phase III clinical trials. However, we have not yet conquered the disease, and research and development on vaccines and therapeutics should continue at maximum speed and effort. Therefore, it is time to welcome contributions to this Special Issue of Viruses, “Vaccines and Therapeutics against Coronaviruses”. The aim is to provide comprehensive information on all aspects of coronavirus research and development on vaccines and therapeutics. To achieve this goal, it is essential to understand the biology and virology of coronaviruses. Application of bioinformatics, mathematics, genomics, structural biology, and modeling is an essential part of developing safe and efficient vaccines and therapeutics. We also need to develop the best tools and strategies possible for vaccine and drug delivery systems. Epidemiology and diagnostics are also important areas to discuss. Finally, another aim is to outline the strategy for confronting future emerging outbreaks caused by coronaviruses or some other novel virus. We cordially invite you to contribute to the Special Issue “Vaccines and Therapeutics against Coronaviruses” to advance our knowledge on coronaviruses and to discover the means to overcome the pandemic together.
Dr. Kenneth Lundstrom
Dr. Alaa A. A. Aljabali
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.